$IMUC
EOM Pharmaceutical Holdings, Inc.

2017 Q4 Form 10-Q Financial Statement

#000082241117000003 Filed on November 21, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.108M $1.137M $1.950M
YoY Change -43.16% 24.98% 3.17%
% of Gross Profit
Research & Development -$676.7K $2.764M $5.370M
YoY Change -112.6% -39.45% 31.94%
% of Gross Profit
Depreciation & Amortization $640.00 $13.94K $20.00K
YoY Change -96.8% -19.21% 0.0%
% of Gross Profit
Operating Expenses $431.7K $3.901M $7.320M
YoY Change -94.1% -28.71% 38.64%
Operating Profit -$3.901M
YoY Change -28.71%
Interest Expense $400.00 $0.00 $990.0K
YoY Change -99.96% -100.0% 110.64%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$431.3K -$3.901M -$6.320M
YoY Change -93.18% -18.69% 31.39%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$431.3K -$3.901M -$6.320M
YoY Change -93.18% -18.69% 31.39%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$123.1K -$2.548M -$1.780M
COMMON SHARES
Basic Shares Outstanding 35.20M shares 15.84M shares 137.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.630M $6.005M $11.44M
YoY Change -42.05% -60.75% -49.38%
Cash & Equivalents $6.630M $6.005M $11.44M
Short-Term Investments
Other Short-Term Assets $378.8K $710.8K $791.5K
YoY Change -52.14% 12.61% -0.74%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.009M $6.716M $13.41M
YoY Change -47.75% -60.42% -45.38%
LONG-TERM ASSETS
Property, Plant & Equipment $568.00 $59.66K $109.8K
YoY Change -99.48% -52.92% -39.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $3.370M
YoY Change -100.0% -100.0% -36.89%
Total Long-Term Assets $568.00 $59.66K $3.475M
YoY Change -99.98% -98.87% -37.06%
TOTAL ASSETS
Total Short-Term Assets $7.009M $6.716M $13.41M
Total Long-Term Assets $568.00 $59.66K $3.475M
Total Assets $7.009M $6.776M $16.89M
YoY Change -58.5% -69.52% -43.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.775M $3.766M $1.342M
YoY Change 32.22% 698.4% 15.58%
Accrued Expenses $295.6K $3.098M $787.0K
YoY Change -62.44% 243.28% 147.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.361M $7.299M $3.239M
YoY Change -27.11% 321.07% 42.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $7.520M
YoY Change -100.0% -100.0% 23.48%
Total Long-Term Liabilities $0.00 $0.00 $7.520M
YoY Change -100.0% -100.0% 23.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.361M $7.299M $3.239M
Total Long-Term Liabilities $0.00 $0.00 $7.520M
Total Liabilities $2.361M $7.299M $10.76M
YoY Change -78.06% -31.12% 28.66%
SHAREHOLDERS EQUITY
Retained Earnings -$116.4M -$116.0M -$96.22M
YoY Change 21.01% 29.05% 29.79%
Common Stock $121.1M $115.5M $102.4M
YoY Change 18.31% 13.75% 6.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.648M -$523.3K $6.132M
YoY Change
Total Liabilities & Shareholders Equity $7.009M $6.776M $16.89M
YoY Change -58.5% -69.52% -43.85%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q4
OPERATING ACTIVITIES
Net Income -$431.3K -$3.901M -$6.320M
YoY Change -93.18% -18.69% 31.39%
Depreciation, Depletion And Amortization $640.00 $13.94K $20.00K
YoY Change -96.8% -19.21% 0.0%
Cash From Operating Activities -$4.929M -$2.220M -$3.740M
YoY Change 31.79% -54.98% -35.74%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.330K $0.00
YoY Change
Cash From Investing Activities $0.00 $1.330K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.553M 6.410M -120.0K
YoY Change -4727.87% -22.59% -103.02%
NET CHANGE
Cash From Operating Activities -4.929M -2.220M -3.740M
Cash From Investing Activities 0.000 1.330K 0.000
Cash From Financing Activities 5.553M 6.410M -120.0K
Net Change In Cash 624.6K 4.191M -3.860M
YoY Change -116.18% 25.11% 109.78%
FREE CASH FLOW
Cash From Operating Activities -$4.929M -$2.220M -$3.740M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$4.929M -$2.220M -$3.740M
YoY Change 31.79% -54.98% -35.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000822411
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35195343 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
ImmunoCellular Therapeutics, Ltd.
dei Trading Symbol
TradingSymbol
IMUC
imuc Adjustments To Additional Paid In Capital Accretion Of Conversion Feature Of Preferred Stock
AdjustmentsToAdditionalPaidInCapitalAccretionOfConversionFeatureOfPreferredStock
1576986 USD
imuc Adjustments To Additional Paid In Capital Preferred Stock Dividends
AdjustmentsToAdditionalPaidInCapitalPreferredStockDividends
6160 USD
imuc Adjustments To Additional Paid In Capital Preferred Stock With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalPreferredStockWithConversionFeature
1576986 USD
imuc Adjustments To Additional Paid In Capital Public Offering Accretion Of Issuance Discount
AdjustmentsToAdditionalPaidInCapitalPublicOfferingAccretionOfIssuanceDiscount
571854 USD
imuc Adjustments To Additional Paid In Capital Public Offering Issuance Discount
AdjustmentsToAdditionalPaidInCapitalPublicOfferingIssuanceDiscount
571854 USD
imuc Adjustments To Additional Paid In Capital Warrant Repricing Accretion Of Financing Charge
AdjustmentsToAdditionalPaidInCapitalWarrantRepricingAccretionOfFinancingCharge
23311 USD
imuc Adjustments To Additional Paid In Capital Warrant Repricing Financing Charge
AdjustmentsToAdditionalPaidInCapitalWarrantRepricingFinancingCharge
23311 USD
imuc Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
2148180 USD
imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
-0.07
imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
0.00
CY2016Q3 imuc Charge To Financing Expense
ChargeToFinancingExpense
111557 USD
imuc Charge To Financing Expense
ChargeToFinancingExpense
142788 USD
imuc Deemed Dividend From Warrant Repricing
DeemedDividendFromWarrantRepricing
0 USD
CY2017Q3 imuc Charge To Financing Expense
ChargeToFinancingExpense
0 USD
imuc Charge To Financing Expense
ChargeToFinancingExpense
0 USD
CY2016Q3 imuc Deemed Dividend From Warrant Repricing
DeemedDividendFromWarrantRepricing
0 USD
imuc Proceeds From Upfront Payment
ProceedsFromUpfrontPayment
1500000 USD
CY2017Q3 imuc Deemed Dividend From Warrant Repricing
DeemedDividendFromWarrantRepricing
23311 USD
imuc Deemed Dividend From Warrant Repricing
DeemedDividendFromWarrantRepricing
23311 USD
imuc Derivative Instruments Warrants Reclassified To Additional Paid In Capital
DerivativeInstrumentsWarrantsReclassifiedToAdditionalPaidInCapital
0 USD
imuc Derivative Instruments Warrants Reclassified To Additional Paid In Capital
DerivativeInstrumentsWarrantsReclassifiedToAdditionalPaidInCapital
573560 USD
imuc Financing Costs Incurredbut Notyet Paid
FinancingCostsIncurredbutNotyetPaid
75000 USD
imuc Financing Costs Incurredbut Notyet Paid
FinancingCostsIncurredbutNotyetPaid
0 USD
imuc Issuance Of Warrants And Effect Of Repricing
IssuanceOfWarrantsAndEffectOfRepricing
2427183 USD
imuc Issuance Of Warrants And Effect Of Repricing
IssuanceOfWarrantsAndEffectOfRepricing
0 USD
imuc Liability Reclassified To Other Current Assets
LiabilityReclassifiedToOtherCurrentAssets
0 USD
imuc Liability Reclassified To Other Current Assets
LiabilityReclassifiedToOtherCurrentAssets
108984 USD
CY2016Q3 imuc Preferred Stock Accretion Of Beneficial Conversion Feature
PreferredStockAccretionOfBeneficialConversionFeature
0 USD
imuc Preferred Stock Accretion Of Beneficial Conversion Feature
PreferredStockAccretionOfBeneficialConversionFeature
0 USD
CY2017Q3 imuc Preferred Stock Accretion Of Beneficial Conversion Feature
PreferredStockAccretionOfBeneficialConversionFeature
1576986 USD
imuc Preferred Stock Accretion Of Beneficial Conversion Feature
PreferredStockAccretionOfBeneficialConversionFeature
1576986 USD
CY2016Q3 imuc Preferred Stock Accretion Of Issue Discount
PreferredStockAccretionOfIssueDiscount
0 USD
imuc Preferred Stock Accretion Of Issue Discount
PreferredStockAccretionOfIssueDiscount
0 USD
CY2017Q3 imuc Preferred Stock Accretion Of Issue Discount
PreferredStockAccretionOfIssueDiscount
571854 USD
imuc Preferred Stock Accretion Of Issue Discount
PreferredStockAccretionOfIssueDiscount
571854 USD
imuc Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering
6629619 USD
imuc Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering
0 USD
imuc Proceeds From Upfront Payment
ProceedsFromUpfrontPayment
0 USD
imuc Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate
0
imuc Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate
0
imuc Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
41000 USD
imuc Supplies Write Off
SuppliesWriteOff
0 USD
imuc Supplies Write Off
SuppliesWriteOff
2349404 USD
imuc Warrant Liability Gain Loss Included In Earnings
WarrantLiabilityGainLossIncludedInEarnings
2045082 USD
imuc Warrant Liability Gain Loss Included In Earnings
WarrantLiabilityGainLossIncludedInEarnings
0 USD
imuc Warrants Exercised
WarrantsExercised
0 USD
imuc Warrants Exercised
WarrantsExercised
0 USD
CY2017Q3 imuc Working Capital Deficit
WorkingCapitalDeficit
582967 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1342126 USD
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3765636 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
786953 USD
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3098320 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
266203 USD
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
262313 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
102354844 USD
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
115486679 USD
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
551340 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1917224 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1712687 shares
CY2016Q4 us-gaap Assets
Assets
16889990 USD
CY2017Q3 us-gaap Assets
Assets
6775761 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
13414789 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
6716101 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22604481 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15297823 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11437118 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6005298 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7306658 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5431820 USD
CY2016Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
3462617 USD
CY2017Q3 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
466601 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3444859 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23788510 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3444859 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23788510 shares
CY2017Q3 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
3121042 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
344 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
2378 USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
2022 USD
us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
573560 USD
CY2016Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
100216 USD
CY2017Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2017Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27267545 USD
CY2017Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30012377 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3090903 USD
CY2017Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3267926 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30358448 USD
CY2017Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33280303 USD
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1955514 USD
CY2017Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
0 USD
CY2016Q3 us-gaap Depreciation
Depreciation
17256 USD
us-gaap Depreciation
Depreciation
58219 USD
CY2017Q3 us-gaap Depreciation
Depreciation
13941 USD
us-gaap Depreciation
Depreciation
47131 USD
CY2016Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 USD
us-gaap Operating Expenses
OperatingExpenses
16792720 USD
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.21
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.00
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.19
CY2016Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1118411 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
2045082 USD
CY2017Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
CY2017Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6160 USD
us-gaap Dividends Preferred Stock
DividendsPreferredStock
6160 USD
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.58
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.19
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.13
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.33
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1109864 USD
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
435112 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P11M
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
244046 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1706 USD
CY2016Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2017Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
7719440 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
908380 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3058027 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1137329 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2918773 USD
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4797825 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15760741 USD
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3900879 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13880712 USD
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-764613 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2423510 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
584920 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2202383 USD
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-655395 USD
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-431268 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-674752 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
889146 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
882683 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-166200 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2036196 USD
us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
377837 USD
us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
-146430 USD
CY2016Q3 us-gaap Interest Expense
InterestExpense
342323 USD
us-gaap Interest Expense
InterestExpense
889146 USD
CY2017Q3 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
882683 USD
us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9920 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
18831 USD
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
109 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
4284 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
8554 USD
CY2016Q4 us-gaap Liabilities
Liabilities
10758244 USD
CY2017Q3 us-gaap Liabilities
Liabilities
7299068 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16889990 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6775761 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3238943 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7299068 USD
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
6945741 USD
CY2017Q3 us-gaap Long Term Debt
LongTermDebt
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8820806 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6309757 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4015 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1326 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16123449 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11742903 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-4797825 USD
us-gaap Net Income Loss
NetIncomeLoss
-15760741 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3900879 USD
us-gaap Net Income Loss
NetIncomeLoss
-13880712 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4797825 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15760741 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6079190 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16059023 USD
us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
0 USD
us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
573560 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
5472276 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
3900988 USD
us-gaap Operating Expenses
OperatingExpenses
20721753 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5472276 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-16792720 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3900988 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-20721753 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
81000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
63000 USD
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
68200000 USD
CY2017Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
75000000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
791485 USD
CY2017Q3 us-gaap Other Assets Current
OtherAssetsCurrent
710803 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4015 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
102 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1309648 USD
CY2017Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
0 USD
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
0 USD
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
4120577 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
691187 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1326 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2189180 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
376026 USD
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
321973 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
109823 USD
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59660 USD
CY2013Q2 us-gaap Rental Properties
RentalProperties
8063 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3000000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4563896 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13734693 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2763659 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17802980 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96223442 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116012364 USD
CY2016Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2017Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
759424 USD
us-gaap Share Based Compensation
ShareBasedCompensation
442558 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3937 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.827
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20581 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
162665 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
142084 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
43.11
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.11
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
116624 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
48.51
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
108.42
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y6M5D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3469021 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
442558 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
6131746 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
-523307 USD
CY2016Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.025
CY2016Q4 us-gaap Supplies
Supplies
1186186 USD
CY2017Q3 us-gaap Supplies
Supplies
0 USD
CY2017Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5349725 USD
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2921855 USD
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1958775 USD
CY2016Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2340876 USD
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
573560 USD
CY2017Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0 USD
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3033401 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2547609 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15312029 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7524037 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates </font><font style="font-family:inherit;font-size:10pt;">&#8211; The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions, which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these condensed consolidated financial statements.</font></div></div>

Files In Submission

Name View Source Status
0000822411-17-000003-index-headers.html Edgar Link pending
0000822411-17-000003-index.html Edgar Link pending
0000822411-17-000003.txt Edgar Link pending
0000822411-17-000003-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imuc-20170930.xml Edgar Link completed
imuc-20170930.xsd Edgar Link pending
imuc-20170930_cal.xml Edgar Link unprocessable
imuc-20170930_def.xml Edgar Link unprocessable
imuc-20170930_lab.xml Edgar Link unprocessable
imuc-20170930_pre.xml Edgar Link unprocessable
imuc-93017x10q.htm Edgar Link pending
imuc-93017xexhibit311.htm Edgar Link pending
imuc-93017xexhibit312.htm Edgar Link pending
imuc-93017xexhibit321.htm Edgar Link pending
imuc-93017xexhibit322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending